Kallikrein

Sino Biological offers a comprehensive set of tools for research on kallikreins, including recombinant proteins, antibodies (rabbit mAbs, mouse mAbs, and rabbit pAbs), ELISA kits, and ORF cDNA clones.

Kallikrein Products

• KLK1 / Kallikrein 1
• KLK5 / Kallikrein 5
• KLK8 / Kallikrein 8
• KLK3 / Kallikrein 3
• KLK6 / Kallikrein 6 / Neurosin
• KLK11 / Kallikrein 11
• KLK4 / Kallikrein 4
• KLK7 / Kallikrein 7
• KLK13 / Kallikrein 13

Kallikrein Background

Kallikreins are a sub-family of serine proteases, with a high degree of substrate specificity and diverse expression in various tissues and biological fluids. The human kallikrein peptidase (KLK) family consists of 15 highly conserved serine proteases, and they are divided into two groups, plasma and tissue kallikreins, which differ significantly in their molecular weight, gene structure, substrate specificity, immunological characteristics, and type of the kinin released. Plasma kallikrein is expressed solely in liver and it is involved in blood clotting, fibrinolysis, regulation of blood pressure and inflammatory reactions. Tissue kallikreins are a large group of enzymes which have substantial similarities at gene and protein level. Tissue kallikreins are involved in the post-translational processing of the polypeptides (like kininogen) and releasing potential biologically active peptides (like kinin). It has been demonstrated that tissue kallikrein through kinin B2 receptor signaling exhibits a wide spectrum of beneficial effects by reducing cardiac and renal injuries, restenosis and ischemic stroke, and by promoting angiogenesis and skin wound healing, independent of blood pressure reduction. Several members of the kallikrein family have been reported as potential biomarkers of a variety of cancers, including prostate, breast, ovarian, gastrointestinal, lung, and brain malignancies.

Kallikrein Related Studies

1. Bhoola KD, et al. (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 44(1):1-80.
2. Emami N, et al. (2008) Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem. 54(10):1600-7.
3. Chao J, et al. (2010) Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem. 391(4):345-55.
4. Oikonomopoulou K, et al. (2010) Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. Biol Chem. 391(4):299-310.
5. Pruneau D, et al. (2010) Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy. Curr Opin Investig Drugs. 11(5):507-14.